Alka Khaitan, AIDS2022: IMPAACT 2008 study of VRC01 with ART to promote clearance of HIV-1 infected cells in infants

IMPAACT 2008 is a phase I/II, multisite, randomized open-label study which evaluates the safety and antiviral activity on HIV-1 DNA levels of VRC01 in infants living with HIV-1 beginning combination antiretroviral therapy (cART). Dr Alka Khaitan (Indiana University School of Medicine, Indianapolis, IN, USA) joins touchINFECTIOUS DISEASES to discuss the efficacy ans safety findings of the IMPAACT 2008 study.

The presentation entitled ‘Phase I/II study of monoclonal antibody VRC01 with early antiretroviral therapy to promote clearance of HIV-1 infected cells in infants (IMPAACT 2008)’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.

Questions: 

1. What is VRC01 and what evidence supports its use in infants? (00:17)
2. What were the aims, design and study population of the IMPAACT 2008 clinical trial? (02:02)
3. What were the efficacy and safety findings of the study? (03:57)
4. What will be the next steps in the clinical development of VRC01 in this indication? (05:42)

Disclosures: Alka Khaitan has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.